Evidence map›Paper›PMID 37456212›Full record

ArticleIranian journal of medical sciences2023

A Novel Germline Pathogenic Variant of

Mina Amin, Elaheh Mahmoodi-Khaledi, Sina Narrei, Mehrdad Zeinalian

Open access · greenAbstract readCase Reports
In one paragraph

Article in Iranian journal of medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mina AminDepartment of Cell and Molecular Biology, School of Chemistry, University of Kashan, Kashan, Iran.
Elaheh Mahmoodi-KhalediDepartment of Cell and Molecular Biology, School of Chemistry, University of Kashan, Kashan, Iran.
Sina NarreiAla Cancer Prevention and Control Center, Isfahan, Iran.
Mehrdad ZeinalianAla Cancer Prevention and Control Center, Isfahan, Iran.
University of Kashan · IRIsfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Squamous cell carcinoma (SCC) is the most common human solid tumor and the leading cause of cancer death. SCC of the breast is a very rare type of cancer that has not been well researched. Early identification of the genetic factors involved can lead to early diagnosis and targeted treatment. The present study was conducted in 2018 at Isfahan University of Medical Sciences (Isfahan, Iran). The proband was a 66-year-old woman with SCC of the breast and a positive family history of cancer. Blood DNA samples were used for whole-exome sequencing to identify germline pathogenic variants. Variant annotation and prioritization were done on variant call format files using bioinformatics software tools. The screened variants were confirmed using the Sanger sequencing method. Co-segregation analysis was performed on the blood DNA samples of the first- and second-degree relatives of the proband to assess the presence of the mutation. A novel germline pathogenic variant was identified in the

Indexed as

Carcinoma, Squamous CellExomeAgedFemaleGerm CellsHumansIranPedigreeRecQ HelicasesRecQ HelicasesRECQL4 protein, humanCancerCarcinomaNext generation sequencingSquamous cellWhole exome sequencing

Identifiers

PMID37456212
PMCPMC10349162
OpenAlexW4384492953

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.